Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Leases (2020 - 2025)

Historic Current Leases for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $6.8 million.

  • Foghorn Therapeutics' Current Leases fell 2297.61% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 2297.61%. This contributed to the annual value of $9.1 million for FY2024, which is 644.52% up from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Current Leases is $6.8 million, which was down 2297.61% from $6.2 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Current Leases ranged from a high of $9.1 million in Q1 2025 and a low of $5.7 million during Q2 2022
  • Moreover, its 5-year median value for Current Leases was $7.0 million (2021), whereas its average is $7.3 million.
  • Its Current Leases has fluctuated over the past 5 years, first surged by 758241.76% in 2021, then tumbled by 3188.49% in 2025.
  • Foghorn Therapeutics' Current Leases (Quarter) stood at $7.0 million in 2021, then fell by 14.64% to $6.0 million in 2022, then surged by 42.68% to $8.5 million in 2023, then rose by 6.45% to $9.1 million in 2024, then fell by 25.5% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $6.2 million for Q2 2025, and $9.1 million during Q1 2025.